A detailed history of Capstone Investment Advisors, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Capstone Investment Advisors, LLC holds 60,298 shares of NTLA stock, worth $1.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,298
Holding current value
$1.27 Million
% of portfolio
0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$20.02 - $27.22 $1.21 Million - $1.64 Million
60,298 New
60,298 $1.35 Million
Q4 2023

Feb 12, 2024

BUY
$23.16 - $32.34 $232,711 - $324,952
10,048 Added 20.37%
59,380 $1.81 Million
Q3 2023

Nov 13, 2023

BUY
$31.62 - $45.78 $1.21 Million - $1.75 Million
38,164 Added 341.73%
49,332 $1.56 Million
Q2 2023

Aug 10, 2023

BUY
$34.58 - $46.03 $386,189 - $514,063
11,168 New
11,168 $455,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.6B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Capstone Investment Advisors, LLC Portfolio

Follow Capstone Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capstone Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capstone Investment Advisors, LLC with notifications on news.